Analytical Framework for Examining the Value of Antibacterial Products. Abom


As discussed previously, we assumed the annual number of deaths due to ABOM to be zero. Therefore, the VSL-based mortality costs were assumed to be null.

View full report


"rpt_antibacterials.pdf" (pdf, 1.43Mb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®